Merck (MRK) stock in focus as its lung disease drug Winrevair gains FDA priority review for a label update based on Phase 3 ...

The Cardiac Centre at Al Qassimi Hospital, operated by Emirates Health Services (EHS), has become the first facility in the ...

Liquidia shipped its first FDA-approved product, Yutrepia for pulmonary hypertension in June entering market worth several ...

A 68-year-old woman was referred for investigation of pulmonary artery hypertension. Right heart catheterisation was performed and the tip of the catheter was positioned in the right middle lobe ...

MORRISVILLE, N.C., June 23, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, ...

Pulmonary hypertension (PH) is now defined as mean pulmonary artery pressure >20 mm Hg according to the updated clinical classification from the 6th World Symposium of Pulmonary Hypertension (WSPH) ...

The AKR mouse—a mouse strain susceptible to development of hypertension and metabolic syndrome 190 —has been used to study the mechanisms underlying obesity-related pulmonary vascular remodeling in ...

Group 4: CTEPH (chronic thromboembolic pulmonary hypertension)—In some patients, pulmonary embolism, or blood clots, in the lung’s arteries can form scar-like tissue, blocking or narrowing the ...

If you are diagnosed with pulmonary hypertension (PH) or your doctor suspects PH, it is important for you to see a specialist. Pulmonary arterial hypertension (PAH) is a rare, progressive lung disease ...

This study highlights the vital role of caregivers in supporting women living with pulmonary arterial hypertension (PAH) and underscores the need to enhance caregiver support and address unmet needs ...

BMPER overexpression mitigated the vascular remodeling that characterizes pulmonary arterial hypertension (PAH), according to a preclinical study published in Cellular Signalling. In vivo and in ...

What’s driving this surge? Insmed revealed that its Phase IIb trial for treprostinil palmitil inhalation powder (TPIP) in pulmonary arterial hypertension (PAH) achieved..